Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Multiple Myeloma Cancer Coaching is information and feedback from a long-term Myeloma Survivor. Your MM oncologist and I provide you with information, education and support-
Based on the post and questions below, this MM patient has achieved a multiple myeloma partial remission after several rounds of multiple myeloma chemotherapy.
Dear David, Hope all well with you.
Ken’s blood testing on 23rd of May after being off all medication for 2 months were:
The treatment we followed for a month was 2.6 mg Velcade (bortezomib) once every week, dexamethasone 40 mg every week, and pomalid 4mg X 21 days 9 days off.
His markers now are: M-spike – 1.16 Kappa – 407 Lambda – 5.1 K/L ratio – 79.8
Considering this we have reduced the pomalid to 2mg X 21 days, velcade 2mg either once a week or every alternate week , and decmax remains the same.
What do you think about this? Considering the pain due to the neoplasms is yet there.
The neoplasms that the biopsy revealed above the pelvic bone on Ken’s left side still cause some pain though compared to before treatment much less. On the day that he takes the decmax its disappears and comes back after 2 days.
Since September 2016 the Velcade has been administered to Ken subcutaneously in the stomach and always before and after the area is numbed with an ice pack, the pain starts from the left lower back and goes on to the stomach left side… I have been wondering if there is any relation at all between all this as it is all in the same part of the body.
We have also started some new supplements, which I wanted to discuss with you, kindly address these concerns of mine first.
Thanks as always Warm Regards Jenny Sent from my iPhone
Hi Jenny-
All is well with me, thanks.
If I understand your email, Ken was off all medication for April and May and underwent more chemo though somewhat reduced doses. If this is correct and Ken’s blood levels have improved and his bone pain has improved overall I would say that Ken is trending in the right direction.
I will be specific below.
1) Re the specific numbers- If I read the results above correctly, Ken’s m-spike, Kappa and K/L ratio have all decreased by about 50%. Ken’s KL ratio has decreased even more. The normal Free light chain ranges are:
3.3 to 19.4 mg/L kappa free light chains
5.71 to 26.3 mg/L lambda free light chains
0.26 to 1.65 ratio of kappa/lambda
2) Ken’s MM responded after a chemo “vacation” so I would say this is good news. My impression from your email is that you are a bit concerned (unhappy) with Ken’s bone pain but can’t complain as the bone pain is less than before.
When you refer to Ken’s “neoplasms” you talk about them as if they are above Ken’s pelvic bone. Are you saying that the pain is not in Ken’s bone but above it? MM can exhibit itself as extramedularyor lesions outside of bones. You should discuss this with your oncologist.
2) Re subcutaneous Velcade injections. I would ask your oncologist if an extramedulary lesion can be negatively affected by a velcade injection near it.
3) Regarding supplementation, yes, there are a number (18) of evidence-based nutritional supplements shown to by cytotoxic to MM.
Please give my best to Ken-
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
Please scroll down the page, post a question or comment and I will reply to you ASAP.
Reduction in 24-hour urinary M-protein by ≥ 90% or to < 200 mg/24 hours.
If the serum and urine M-protein are not measurable (i.e., do not meet the following criteria at time of diagnosis):
Serum M-protein ≥ 1 g/dL
Urine M-protein ≥ 200 mg/24 hours;
then a ≥ 50% decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria (provided the serum free light chain assay shows involved level > 10 mg/dL and the serum free light chain is abnormal).
If serum and urine M-protein and serum-free light assay are not measurable, a ≥ 50% reduction in bone marrow plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was ≥ 30%.
In addition to the above-listed criteria, if soft tissue plasmacytomas were present at baseline, a ≥ 50% reduction in their size is also required.
PR requires two consecutive assessments (by the same method) made at any time before the institution of any new therapy. If radiographic studies were performed, there must be no known evidence of new or progressive bone lesions. Radiographic studies are not required to satisfy PR requirements.
Stable Disease (SD)
Does not meet the criteria for CR, VGPR, PR, or PD.
SD requires two consecutive assessments (by the same method) made at any time before the institution of any new therapy. If radiographic studies were performed, there must be no known evidence of new or progressive bone lesions. Radiographic studies are not required to satisfy SD requirements.
